Can REYOBIQ improve Plus Therapeutics’ path in pediatric high-grade glioma and ependymoma?
Plus Therapeutics won orphan drug designation for REYOBIQ in pediatric malignant gliomas. Read what it changes for CNS cancer development.
Pharma & Biotech
Pharma & Biotech
Adaptin Bio prepares Phase 1 glioblastoma trial following preclinical progress in brain cancer candidate
Find out how Adaptin Bio is preparing a Phase 1 glioblastoma trial and why its preclinical progress matters for brain cancer treatment innovation.
Pharma & Biotech
Curasight begins Phase 1 trial of uTREAT in glioblastoma, marking shift to clinical-stage radiopharma development
Curasight A/S has dosed the first patient in a Phase 1 clinical trial of uTREAT for glioblastoma, launching the therapeutic half of its uPAR-targeting theranostic platform alongside its companion diagnostic, uTRACE, which is already in Phase 2 for prostate cancer. How curative ambitions shift when a theranostic platform enters human testing in glioblastoma Curasight’s advancement
Pharma & Biotech
T-MAXIMUM’s MT027 clears FDA hurdle for glioblastoma in major step for solid tumor CAR-T
T-MAXIMUM’s MT027 CAR-T therapy for glioblastoma enters Phase II after FDA clearance. Find out what this means for solid tumor cell therapy.